Community-acquired urinary tract infection in hospitalized children: etiology and antimicrobial resistance. A comparison between first episode and recurrent infection.
Urinary tract infection (UTI) is common in infants and children, and Escherichia coli is the leading pathogen. The aims of this study were to compare first episode of UTI with recurrent infection, reveal organisms that cause UTI, uropathogen resistance, and presence of bacteria producing extended-spectrum β-lactamase (ESBL). The first-UTI group included 456 children. E coli was the leading pathogen (80.5%), and Pseudomonas aeruginosa was found in 1.5%. The uropathogens were resistant to gentamicin (3.41%) and cefuroxime (5.71%), and highly resistant to cefamezin (37.39%). The recurrent-infection group included 106 children. E coli was also the leading pathogen, but 7.5% of the isolates were P aeruginosa (P = .002 compared with first-episode group); 6.6% were ESBL-producing bacteria compared with 1.1% in the first-episode group (P = .002). E coli is the leading pathogen in both groups. P aeruginosa and ESBL-producing bacteria were more common in the recurrent infection group.
Emek Medical Center, Afula, Israel The Ruth and Baruch Rappaport School of Medicine, Technion, Haifa, Israel sakran_w@clalit.org.il.
Waheeb
W
Sakran
The Ruth and Baruch Rappaport School of Medicine, Technion, Haifa, Israel Pediatric Nephrology Unit, Emek Medical Center, Afula, Israel.
Vladislav
V
Smolkin
Emek Medical Center, Afula, Israel.
Ahmad
A
Odetalla
Emek Medical Center, Afula, Israel Pediatric Nephrology Unit, Emek Medical Center, Afula, Israel.
Raphael
R
Halevy
Emek Medical Center, Afula, Israel The Ruth and Baruch Rappaport School of Medicine, Technion, Haifa, Israel.
Ariel
A
Koren
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002437:Cefazolin / Q000627:therapeutic use; D002444:Cefuroxime / Q000627:therapeutic use; D002673:Child, Hospitalized / Q000706:statistics & numerical data*; D002675:Child, Preschool; D017714:Community-Acquired Infections / Q000453:epidemiology; D024901:Drug Resistance, Multiple, Bacterial; D004926:Escherichia coli; D005260:Female; D005839:Gentamicins / Q000627:therapeutic use; D006801:Humans; D007223:Infant; D007557:Israel / Q000453:epidemiology; D008297:Male; D011550:Pseudomonas aeruginosa; D012008:Recurrence; D012189:Retrospective Studies; D012307:Risk Factors; D014552:Urinary Tract Infections / Q000188:drug therapy* / Q000453:epidemiology*
D000900:Anti-Bacterial Agents; D005839:Gentamicins; D002437:Cefazolin; D002444:Cefuroxime
Escherichia coli; recurrent infection; resistance; urinary tract infection